Arrhythmias & electrophysiology
Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial
Authors' conclusion
This study found that abelacimab consistently reduced bleeding compared with rivaroxaban regardless of age, with the potential for a greater absolute reduction in bleeding with older age.
Study context
- Population
- Patients with atrial fibrillation (AF), analysed by age (<75 vs ≥75 years)625 (49%) ≥75 years
- Participants
- 1,287 patients
- Comparison
- Abelacimab vs rivaroxaban, by age
- Primary endpoint
- Composite of:
- Major
- Clinically relevant nonmajor (CRNM) bleeding
Methodological detailsprespecified analysis, phase 2b, Trial conducted March 2021 to September 2023; analysis February to May 2025
- Prespecified analysis
- Phase 2b
- Trial conducted March 2021 to September 2023; analysis February to May 2025
Primary result
As reported in the abstract
Major or CRNM bleeding, by age
Each group vs rivaroxabanHazard ratio (95% CI)
Abelacimab 90 mgage ≥75 years
0.32(0.17–0.60)
Abelacimab 150 mgage ≥75 years
0.40(0.22–0.73)
Abelacimab 90 mgage <75 years
0.28(0.12–0.61)
Abelacimab 150 mgage <75 years
0.35(0.17–0.70)
- Absolute risk reduction vs rivaroxaban, age ≥75 years (abelacimab 90 and 150 mg)
- 7.1 and 6.2 per 100 patient-years
- Absolute risk reduction vs rivaroxaban, age <75 years (abelacimab 90 and 150 mg)
- 4.7 and 4.2 per 100 patient-years
- Age modeled continuously: bleeding risk tended to increase with age with rivaroxaban but remained stable with abelacimab
- P for interaction, .33
Further findings
Bleeding risk with age modeled continuously
- Bleeding risk tended to increase with age with rivaroxaban but remained stable with abelacimab
- P for interaction, .33
Original publication
Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial. JAMA Cardiol. Published 1 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →